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Core evidence place in therapy summary for bevacizumab in NSCLC
Outcome measure Evidence Implications
Patient-oriented evidence
Progression-free survival Clear Addition of bevacizumab to platinum-based doublet chemotherapy (carboplatin/paclitaxel) followed by
bevacizumab monotherapy until disease progression significantly improves progression-free survival compared
with chemotherapy alone in the first-line treatment of predominantly nonsquamous, “wet IIIB”/stage IV
(metastatic), or recurrent NSCLC
Survival Clear Addition of bevacizumab to platinum-based chemotherapy (carboplatin/paclitaxel) followed by bevacizumab
monotherapy until disease progression significantly improves overall survival compared with chemotherapy
alone in the first-line treatment of nonsquamous, wet IIIB/stage IV, or recurrent NSCLC
Quality of life No evidence
Safety and tolerability Substantial Tumors characterized as having a squamous cell histology appear to be a major risk factor associated with
bleeding. There is also an increased risk of hypertension, capillary leakage, and proteinuria, which is generally
asymptomatic and not associated with renal dysfunction
Disease-oriented evidence
Response rate Clear Addition of bevacizumab to platinum-based doublet chemotherapy (carboplatin/paclitaxel) followed by
bevacizumab monotherapy until disease progression significantly increases the overall response rate compared
with chemotherapy alone in patients with previously untreated wet IIIB/stage IV, or recurrent NSCLC
Economic evidence
Cost effectiveness Limited  Adding bevacizumab may not be cost effective in terms of cost per life-year gained
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Abstract
Introduction: Lung cancer is the leading cause of cancer-related mortality. Platinum-based chemotherapy is the usual first-line treatment
for advanced nonsmall cell lung cancer (NSCLC), although an efficacy plateau has been reached with this approach. Bevacizumab is a
recombinant, humanized, monoclonal antibody to vascular endothelial growth factor, which inhibits tumor angiogenesis and is being
evaluated as a different mechanism to improve outcomes in patients with stage IIIB/stage IV (metastatic) NSCLC.
Aims: To review the emerging evidence for the potential use of bevacizumab in stage IIIB/IV NSCLC.
Evidence review: Adding bevacizumab to carboplatin plus paclitaxel improves response rates and significantly prolongs time to disease
progression, which translates into a significant extension of overall survival (median 2.3 months in one key study). Low levels of
intracellular adhesion molecule-1 are associated with better response. Preliminary evidence suggests that combining bevacizumab with
erlotinib could improve outcomes in patients relapsing following platinum-based chemotherapy. Episodes of bleeding (particularly
pulmonary hemorrhage) are the predominant adverse events associated with bevacizumab, probably a result of tumor disintegration. 
There is limited evidence that the high acquisition cost of bevacizumab unfavorably affects assessment of its cost effectiveness,
although there are few other treatment options in these patients with poor prognosis.
Place in therapy: The encouraging results obtained with bevacizumab in patients with NSCLC are leading to its adoption in some
treatment guidelines. Emerging evidence indicates improved outcomes when bevacizumab is added to carboplatin/paclitaxel in
previously untreated patients with NSCLC, and when used with erlotinib in patients who have relapsed following platinum-based
chemotherapy.
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Bevacizumab (Avastin®; Genentech/Roche), a recombinant,
humanized, monoclonal antibody directed against human
vascular endothelial growth factor (VEGF), is indicated in the US
for first-line treatment of nonsmall cell lung cancer (NSCLC) in
combination with carboplatin and paclitaxel (Anon. 2006).
This review summarizes the disease background, current therapy
options, and unmet medical needs in NSCLC, and examines the
current evidence for the use of bevacizumab in this indication.
Various outcomes are evaluated, including response rates, time 
to progression, survival, and safety/tolerability profiles for
bevacizumab in combination with platinum-based chemotherapy
(carboplatin plus paclitaxel) or the small molecule HER-1/
epidermal growth factor receptor (EGFR) inhibitor, erlotinib, in the
treatment of stage IIIB with malignant pleural effusion (also known
as “wet IIIB” disease) and stage IV (metastatic) NSCLC (excluding
predominantly squamous cell tumors). Finally, the potential place
in therapy for bevacizumab in NSCLC is discussed. 
Methods
The English language medical literature was searched between
April 21 and November 18, 2005 and again on January 11 and
September 19, 2006, in the following databases:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
• EMBASE, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluations Database
(NHSEED), Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/darehp.htm. All fields searched
in all three databases together
• NHS HTA, http://www.ncchta.org
• National Guideline Clearinghouse, http://www.guideline.gov
• Cochrane Database of Systematic Reviews (CDSR),
http://cochrane.org/index0.htm
• Clinical Evidence (BMJ), http://clinicalevidence.com
• EBM Reviews [American College of Physicians (ACP) Journal
Club], http://www.acpjc.org
The search terms used were “bevacizumab AND lung OR
NSCLC,” and the cut-off dates were from the beginning of the
database to the date of the search.
The proceedings of the following oncology society meetings were
also searched for relevant abstracts, again using the search terms
“bevacizumab AND lung OR NSCLC.”
• American Society for Clinical Oncology (ASCO) 2003–2006
• American Association for Cancer Research (AACR) 2005, 2006 
• European Society for Medical Oncology (ESMO) 2004
• World Congress on Lung Cancer (WCLC) 2003, 2005
• The Euopean Cancer Congress (ECCO) 2003, 2005
The levels of evidence identified from the literature searches are
summarized in Table 1.
Disease overview
Epidemiology and risk factors
Lung cancer is estimated to be the second most common cancer
in women (after breast cancer) and the second most common
cancer in men (after prostate cancer). In addition, lung cancer 
is the leading cause of cancer-related death in both males 
and females (Jemal et al. 2005). One in 13 males and one in 
18 females are expected to develop lung cancer at some point
during their lives (Jemal et al. 2005). The majority of patients with
lung cancer are 35–75 years of age, with a peak incidence
between the ages of 55–65 years (Jemal et al. 2005).
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Category Number of records
Full papers Abstracts
Initial search 422 7
records excluded 24 14
records included 4 13
Search update, new records 0 9
records excluded 0 2
records included 07
Preclinical evidence 0 2
Level 1 clinical evidence
(systematic review, meta analysis)
1a 1b
Level 2 clinical evidence (RCT) 2 4c
Level ≥3 clinical evidence
trials other than RCT 1 12d
case reports
Economic evidence 0 2
For definition of levels of evidence, see Editorial Information on inside back cover.
aNational Comprehensive Cancer Network (NCCN) updated clinical practice guidelines 
in October 2005 to include bevacizumab combined with chemotherapy in the first-line
treatment of advanced NSCLC.
bMeta analysis of thromboembolic events in five trials of chemotherapy ± bevacizumab 
in patients with breast cancer, colorectal cancer, and NSCLC.
cThree abstracts were superseded by the publication of the corresponding full papers.
dSix abstracts were susperseded by the publication of the corresponding full paper. 
NSCLC, nonsmall cell lung cancer; RCT, randomized controlled trial.
Table 1 | Evidence base included in the review33
Epidemiologic studies have demonstrated a clear causal
relationship between tobacco exposure and the development of
lung cancer. Smoking is responsible for ~90% of lung cancer
cases, and changes in lung cancer incidence and mortality over
time have paralleled changes in the prevalence of cigarette
smoking. There is also evidence for a dose–response relationship
between cigarette consumption and the development of lung
cancer, and cessation of smoking leads to a progressive
reduction in lung cancer risk over time (Shopland 1991; Sasco 
et al. 2004; Wakai et al. 2005). 
Independent of smoking status, lung cancer risk is also increased
by exposure to other carcinogens such as asbestos (Hodgson 
& Jones 1986; Kjuus et al. 1986; Mossman et al. 1990; Marsh &
Mossman 1998) and exposure to radon gas (Radford 1985; 
Harley et al. 1986; Nero 1986; Samet 1989), which is formed from
the natural decay of uranium found in varying quantities in rocks
and soils. 
Some individuals may have a genetic predisposition to developing
lung cancer. Several lines of evidence support this hypothesis.
Lung cancer risk appears to be increased in patients with chronic
obstructive pulmonary disease (COPD), even after correction for
cigarette consumption. As COPD appears to have a familial
association, this suggests that some individuals may have an
inherited genetic predisposition to developing both COPD and
lung cancer (Sellers et al. 1990; Minna et al. 1991). In addition, first
degree relatives of patients with lung cancer appear to have an
increased risk of developing lung cancer, compared with unrelated
controls (Tokuhata & Lilienfeld 1963; Ooi et al. 1986). 
NSCLC histologic subtypes 
Nonsmall cell lung cancer (NSCLC) is the most common form of lung
cancer, accounting for ~80% lung cancer cases, whereas small cell
lung cancer (SCLC) accounts for the remaining 20% of cases (Rivera
et al. 2001; Jemal et al. 2004). It is important to distinguish between
SCLC and NSCLC as the distinction dictates treatment options. 
NSCLC is divided into three histologic subtypes: adenocarcinoma,
squamous cell carcinoma, and large cell carcinoma (Fig. 1).
Adenocarcinomas tend to be peripherally located and frequently
metastasize before the symptoms of local disease are apparent.
Squamous cell carcinomas have the strongest association with
smoking of the NSCLC subtypes, and are usually centrally located,
generally remain localized, and have a tendency to cavitate. Large
cell carcinomas consist of large cells with abundant cytoplasm,
large nuclei, and prominent nucleoli. 
Lung tumors often exhibit two or more histologic patterns 
(Fraire et al. 1987). Sometimes the quality and nature of the tissue
available for pathologic review can lead to a classification of
“NSCLC not otherwise specified.” 
Traditionally, the distinction between different NSCLC subtypes
has not guided treatment decisions. However, as will be
discussed later, this is starting to change with the development of
novel targeted agents such as bevacizumab. 
Disease staging
Once a histologic diagnosis of NSCLC has been established, it is
important to establish the stage of the disease to determine the
goals of therapy and treatment options. The TNM staging system
is used to establish how localized or widespread the disease is.
Information on the tumor (T) (i.e. how big it is and how far it has
spread within the lung and to nearby organs), lymph node
involvement (N), and the presence or absence of distant
metastases (M) are collated, enabling an overall stage to be
assigned (Mountain 1986). Criteria for T, N, and M assignments
are summarized in Table 2. How T, N, and M assignments
translate into an overall disease stage is explained in Table 3. 
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SCLC NSCLC
Adenocarcinoma
Squamous cell carcinoma
Large cell carcinoma
Lung cancer
Fig. 1 | Lung cancer: histologic subtypes. NSCLC, nonsmall cell
lung cancer; SCLC, small cell lung cancer
Table 2 | NSCLC: TNM staging (http://www.
health-alliance.com/Cancer/Lung/staging.html)
Stage Characteristics
Tumor (T)
T1 Tumor ≤3 cm in greatest dimension, no proximal invasion 
T2 Tumor >3 cm in diameter or involves the main bronchus
or the tumor has caused partial collapse of the lung or
the tumor has invaded the visceral pleura
T3 The tumor has invaded the chest wall, the mediastinal
pleura, the diaphragm or the pericardium, or the tumor
has caused the whole lung to collapse
T4 The tumor has invaded the mediastinum or there is
malignant pleural effusion
Nodes (N)
N0 No nodal involvement
N1 Involvement of the lymph nodes nearest the affected lung
N2 Involvement of mediastinal lymph nodes on the same
side of the chest as the affected lung or the lymph nodes
just under where the windpipe branches off to each lung
N3 Involvement of nodes on the opposite side of the chest to
the affected lung or involvement of nodes above either of
the collar bone bones
Metastasis (M)
M0 No signs of tumor spread to another lobe or any other
distant metastasis
M1 Tumor spread to another lobe of the lung or distant
metastases Stage I NSCLC represents a tumor that has not spread to the
lymph nodes. The major difference between stage IA and IB
disease is in the size of the primary tumor. Stage II NSCLC is
characterized by a primary tumor that has spread to the hilar
lymph nodes on the same side of the chest as the tumor. A tumor
involving the chest wall without hilar node involvement is also
considered stage II disease. Stage IIIA NSCLC includes tumors
that have invaded the chest wall, diaphragm, the pleura of the
mediastinum or heart, with hilar or mediastinal node involvement
on the same side of the chest as the primary tumor. Stage IIIB
disease includes any size tumor that has invaded any of the vital
structures of the mediastinum, the carina, or the spine, with or
without lymph node involvement. 
A unique form of stage IIIB NSCLC involves a lung tumor and
presence of tumor cells in the pleural fluid (malignant
pleural effusion) but shows no evidence of metastatic disease.
This is often referred to as wet IIIB disease, and is treated in the
same way as stage IV NSCLC. Finally, the most advanced stage
of NSCLC, stage IV disease, refers to the presence of
distant metastases, i.e. the spread of the tumor beyond regional
lymph nodes.
Goals of therapy
For patients who present with operable NSCLC (generally stage
I–II disease) the goal of therapy is usually to eliminate the tumor
completely (i.e. to achieve a cure). A cure is also achieved in
20–30% of patients with locally advanced (stage III) disease. For
the remaining 70–80% of patients with locally advanced disease
who are not cured, multimodality treatment may be prescribed
with the aim of achieving as complete a response as possible. 
Conversely, for the one in three patients who present with
incurable, wet IIIB or stage IV NSCLC, the goals of therapy are
palliative (i.e. to reduce tumor burden, relieve signs and
symptoms, improve quality of life, and prolong survival). In
addition, factors such as patient age and performance status
affect a patient’s ability to tolerate treatment—older patients and
those with poor performance status may be less able to tolerate
aggressive therapy, which in turn affects treatment goals.
Evaluating response to therapy
Response to treatment and disease progression in NSCLC are
usually determined using the Response Evaluation Criteria In
Solid Tumours (RECIST). RECIST (Therasse et al. 2000) differs
from the “older” World Health Organization (WHO) criteria in how
tumor reduction is measured. The WHO criteria measure tumor
reduction in two dimensions, whereas the RECIST criteria
measure tumor reduction in one dimension, which makes tumor
measurement easier and is as effective as bidimensional
measurement for evaluating tumor responses. 
Current therapy options
Despite recent advances in the treatment of NSCLC, only a
small proportion of patients are diagnosed early enough to be
cured with surgery or, in some cases, radiation therapy. Only
~30% of cases of NSCLC cases are diagnosed early enough to
be cured by surgery (Carney & Hansen 2000) and only ~50% of
patients who undergo surgical resection are still alive 5 years
later (Evans 2004). Several treatment guidelines have been
published (Detterbeck et al. 2003; Jett et al. 2003; Kvale et al.
2003; Mathur et al. 2003; Robinson et al. 2003; Scott et al.
2003; Smythe 2003; Socinski et al. 2003; Pfister et al. 2004).
Treatment options depend upon the stage of disease (as
discussed below). 
Stage I–II NSCLC 
For patients with stage I–II NSCLC, surgical resection is the
treatment of choice. For patients with IA disease, surgery alone
is usually sufficient to achieve a cure. For patients with operable
stage IB or IIA disease, adjuvant chemotherapy and/or
radiotherapy is often given with the aim of eliminating any
residual disease left behind after surgery, thus reducing the 
risk of relapse (Evans 2004; Pathak et al. 2004). For patients
diagnosed with stage I–II operable NSCLC the 5-year
postsurgery survival rate is 60–80% (Naruke et al. 1988; Martini
et al. 1992). A comprehensive review of surgery ± adjuvant
therapy in patients with stage I–II NSCLC is beyond the scope
of this article. However, the reader is referred to the guidelines
referenced above. 
Locally advanced stage III NSCLC
Surgery is sometimes an option for patients with stage IIIA and
IIIB NSCLC. Patients with unresectable IIIA or IIIB NSCLC
generally receive platinum-based chemotherapy, radiotherapy, or
chemoradiotherapy, which is potentially curative in some cases
(Dillman et al. 1990; Le Chevalier et al. 1991, 1992; Schaake-
Koning et al. 1992; Sause 1995; Pathak et al. 2004). A complete
review of the treatment of locally advanced NSCLC is beyond the
scope of this article, and the reader is referred to the guidelines
referenced above. 
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Overall stage T N M Operable 5-year survival
IA T1 N0 M0
Yes 47%
IB T2 N0 M0
IIA T1 N1 M0
Yes 26% IIB T2 N1 M0
T3 N0 M0
IIIA T1 N2 M0
Potentially
operable 
in some
cases  8%
T2 N2 M0
T3 N1 M0
T3 N2 M0
IIIB Any T N3 M0
No
T4 Any N M0
IV Any T Any N M1 No  2%
Table 3 | Overall staging based on TNM groups (http://www. 
health-alliance.com/Cancer/Lung/staging.html)
}
}
}
} }35
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Wet IIIB and stage IV (metastatic) NSCLC
Platinum-based chemotherapy has for a long time been the
mainstay of first-line therapy for patients with wet IIIB or stage IV
NSCLC (Ramalingam & Belani 2004). A meta analysis conducted
in 1995 demonstrated improved survival with cisplatin-based
combination chemotherapy compared with older cytotoxic agents
such as alkylating agents [hazard ratio (HR) 0.73 vs 1.26,
respectively] (NSCLC Collaborative Group 1995). In 1990s “new
cytotoxic” agents including docetaxel, paclitaxel, vinorelbine,
gemcitabine, irinotecan, and tirapazamine were developed and
were shown to have impressive single-agent activity in advanced,
inoperable, wet IIIB/stage IV NSCLC. This led to exploring the use
of cisplatin plus new cytotoxic combinations, which were shown to
provide superior response rates and longer survival compared with
cisplatin alone (Table 4). Further randomized trials demonstrated
that doublet combinations consisting of a platinum agent plus a
new cytotoxic were more efficacious than new cytotoxic
monotherapy (Table 4). There are many potential combinations of
platinum agent plus new cytotoxic. However, these platinum-
based doublets are broadly comparable with regard to response
rates and survival (Schiller et al. 2002).
In seeking to enhance the efficacy of doublet combinations, the
use of triplet combinations (i.e. a platinum agent plus two new
cytotoxic agents) was explored. However, the efficacy of triplets
is not superior to that of doublets, and furthermore, triplet therapy
is associated with greater toxicity compared with doublets
(Alberola et al. 2001; Rudd et al. 2002). Consequently, a platinum
agent plus a new cytotoxic doublets remain the first-line standard
of care for patients with advanced, inoperable NSCLC. 
Approximately 30–40% of patients with NSCLC are >70 years of
age (Lee-Chiong & Matthay 1993) and concerns have been raised
regarding the ability of these patients to tolerate platinum-based
chemotherapy. However, for elderly patients with good
performance status (PS), a platinum-based combination is the
preferred treatment, whereas less toxic nonplatinum regimens
may be more appropriate for patients with poor PS (Ramalingam
& Belani 2004). 
Second-line therapy
Single-agent docetaxel, pemetrexed, and erlotinib have each
been approved for the second-line treatment of stage IIIB/IV
NSCLC. 
The approval of docetaxel was based on the outcomes of phase
III trials conducted in patients with disease progression following
platinum-based chemotherapy (Fossella et al. 2000; Shepherd et
al. 2000). These studies demonstrated that, despite low response
rates, second-line treatment with single-agent docetaxel provided
modest improvements in quality of life and survival, compared
with best supportive care, or treatment with either ifosfamide or
vinorelbine.
Pemetrexed was approved following submission of the results of
a large, phase III, randomized study comparing single-agent
docetaxel with single-agent pemetrexed in the second-line
treatment of patients with inoperable stage III/IV NSCLC (Hanna
et al. 2004). This study demonstrated that pemetrexed provided
clinically equivalent efficacy to docetaxel, but with a more
favorable safety profile.
Erlotinib is a small molecule HER-1/EGFR inhibitor that blocks
dysregulated EGFR-mediated intracellular signalling in NSCLC,
inhibiting proliferation and permitting apoptosis of malignant cells.
In a recent phase III study, treatment with erlotinib provided a
significant survival advantage compared with placebo (median 6.7
vs 4.7 months, P<0.001) (Shepherd et al. 2004). In addition,
patients treated with erlotinib experienced significant
improvements in disease-related symptoms compared with
placebo-treated patients, including prolonged time to deterioration
of cough (28.1 vs 15.7 weeks, P=0.04), dyspnea (20.4 vs 12.1
weeks, P=0.03), and pain (12.1 vs 8.1 weeks, P=0.04). 
Unmet needs
Surgery ± adjuvant chemotherapy/radiotherapy is potentially
curative in patients who present with stage I–II and some cases of
IIIA disease. Conversely, palliative, platinum-based chemotherapy
continues to be the mainstay in the first-line treatment of
inoperable, wet IIIB, and stage IV NSCLC, and while the
development of the new cytotoxic agents has widened treatment
options, a chemotherapy efficacy plateau appears to have been
reached (Herbst & Sandler 2004; Ramalingam & Belani 2004).
Consequently, the prognosis for patients with wet IIIB/stage IV
NSCLC remains extremely poor. 
New treatment strategies that combine different mechanisms of
action are therefore urgently required to improve outcomes in
patients with wet IIIB/stage IV NSCLC. A novel agent that is well
tolerated in combination with chemotherapy and other agents
active in NSCLC, and improves response rates, quality of life, and
survival in this patient group would be a major therapeutic
advance.
Angiogenesis: a rational target for therapy
In striving to develop novel, targeted anticancer treatment
strategies, research has recently focused on the development of
agents that inhibit tumor angiogenesis (i.e. inhibit the creation of
new blood vessels to the tumor from preexisting vessels). The
rationale underpinning this strategy is that antiangiogenic therapy
limits the tumor’s vascular supply, limiting tumor growth, and
preventing tumor cells from reaching the systemic circulation and
forming distant metastases (Folkman 1990). It therefore seems
logical that the optimal use of antiangiogenic agents should be in
combination with cytotoxic agents, providing a dual attack on the
tumor itself and its vascular support system. 
Once a tumor develops beyond 2 mm in diameter, the
development of tumor vasculature is stimulated by the
“angiogenic switch,” an imbalance of proangiogenic and
antiangiogenic factors (Brem et al. 1976, 1999; Carmeliet & Jain
2000; Herbst & Fidler 2000; Liekens et al. 2001; Carmeliet 2003).Bevacizumab | place in therapy review
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Treatment regimen Number of patients Response rate (%) Median survival (months) 1-year survival (%) Reference
Single platinum agent vs doublet therapy
Cisplatin
522
11 7.6 28
Sandler et al. 2000
Cisplatin + gemcitabine 30 9.1 39
Cisplatin
446
14 6.4 23
von Pawel et al. 2000
Cisplatin + tirpazamine 28 8.0  34
Cisplatin
432
12 6.0 20
Wozniak et al. 1998
Cisplatin + vinorelbine 26 8.0  36
High-dose cisplatin
414
17 8.6 36
Gatzemeier et al. 2000
Cisplatin + paclitaxel 26 8.1  30
New cytotoxic agent alone vs platinum doublet combinations
Paclitaxel
561
17 6.8 33
Lilenbaum et al. 2002
Paclitaxel + carboplatin 29 8.6  37
Gemcitabine
334
12 9.0 32
Sederholm 2002
Gemcitabine + carboplatin 30 11.0  44
Docetaxel
308
20 8.0 40
Georgoulias et al. 2001
Docetaxel + cisplatin 36 10.0  45
Irinotecan
259
21 11.0 44
Masuda et al.1999
Irinotecan + cisplatin 43 12.0  49
Comparisons of various platinum doublet combinations
Cisplatin + vinorelbine
1218
25 10.1 41
Rodriguez et al. 2001 Cisplatin + docetaxel 32 11.3  46
Carboplatin + docetaxel 24 9.1  38
Cisplatin + paclitaxel
1105
21 7.8 31
Schiller et al. 2002
Cisplatin + gemcitabine 21 8.1  36
Cisplatin + docetaxel 17 7.4  31
Carboplatin + paclitaxel 15 8.2  35
Cisplatin + vinorelbine
408
28 8.0 36
Kelly et al. 2001
Cisplatin + paclitaxel 25 8.0  38
Cisplatin + etoposide
369
14 7.5 37
Belani et al. 1998
Carboplatin + paclitaxel 22 6.3  32
Cisplatin + vindesine
199
22 10.0 41
Niho et al. 1999
Cisplatin + irinitocan 29 10.0  36
NSCLC, nonsmall cell lung cancer.
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The proangiogenic molecule, VEGF, is central to the activation of
the angiogenic switch (Senger et al. 1983; Ferrara et al. 2003;
Hicklin & Ellis 2005) (Fig. 2). The expression of this key molecule
is stimulated by a number of factors in the tumor
microenvironment, including hypoxia, cytokine release,
mechanical stress, and upregulation of oncogenes. The
production of VEGF by the tumor creates a positive feedback loop
by which VEGF-induced angiogenesis allows more tumor growth.
As a result of its rapid growth, the tumor outstrips its blood supply
and the supply of oxygen and nutrients becomes inadequate,
resulting in areas of relative hypoxia. Hypoxia stimulates further
VEGF production, which in turn stimulates further vessel
formation, and once the tumor has entered this vascular phase,
new vessels continue to form for as long as the tumor continues
to grow. In addition, VEGF increases the permeability of the tumor
vasculature to circulating macromolecules, allowing plasma
proteins to leak, resulting in the formation of proangiogenic
stroma. A further consequence of this increased vascular
permeability is that tumor interstitial pressure is increased,
reversing normal pressure gradients within tissues and ultimately
impeding the delivery of chemotherapeutic agents. VEGF-driven
angiogenesis also promotes the contact between blood vessels
and tumor cells, offering a route for tumor cells to invade those
vessels and form distant metastases. Furthermore, excessive
VEGF production results in the formation of vessels that are
immature and hyperpermeable, which facilitates this invasion.
VEGF is also involved in lymphangiogeneisis: the formation of
giant lymphatic vessels, thus providing another potential route by
which the tumor can metastasize (Fig. 2). 
The role of angiogenesis in NSCLC progression is well
established: high microvessel density is a strong prognostic
factor for metastasis and poor survival (Fontanini et al. 1995;
D’Amico et al. 1999; Cox et al. 2000; O’Byrne et al. 2000; Yano et
al. 2000; Meert et al. 2002). In addition, molecular studies have
confirmed that VEGF mRNA is upregulated in lung tumors (Toi et
al. 2001). In NSCLC specimens a positive correlation has been
demonstrated between upregulated VEGF expression, high
tumoral microvessel density, and poor prognosis (Volm et al.1997;
Imoto et al. 1998; Koukourakis et al. 2000; O’Byrne et al. 2000;
Ushijima et al. 2001; Yuan et al. 2001). Inhibition of VEGF
signalling is therefore an attractive and rational therapeutic
strategy in NSCLC (Ferrara 2004; Herbst & Sandler 2004). Anti-
VEGF therapy has the potential to restrict tumor growth and
metastasis by inhibiting angiogenesis and lymphangiogenesis,
and the potential to improve the delivery of concomitant cytotoxic
therapy by reducing tumor interstitial pressure (Herbst & Sandler
2004) (Fig. 2). 
The anti-VEGF, antiangiogenic approaches that have received
most attention to date include:
• inhibiting VEGF itself using neutralizing anti-VEGF monoclonal
antibodies or soluble receptors
• VEGF receptor (VEGFR) blockade using anti-VEGFR
monoclonal antibodies
• inhibiting VEGFR signalling with small molecule VEGFR
tyrosine kinase inhibitors.
Clinical evidence for bevacizumab in NSCLC 
Bevacizumab is a recombinant, humanized, anti-VEGF,
monoclonal antibody that exerts a direct antiangiogenic effect by
binding to and clearing VEGF from the tumor microenvironment
(reviewed by Presta et al. 1997; Salgaller 2003; Herbst & Sandler
2004; Kerr 2004; Sandler at al. 2004a; Adams & Weiner 2005; Culy
2005; Midgley & Kerr 2005; Rhee & Hoff 2005). In a murine
xenograft model of human NSCLC, bevacizumab was shown to
inhibit tumor growth (Kabbinavar et al. 1995). In addition, in
accord with the current thinking that hypoxia-induced production
of VEGF mediates tumoral resistance to radiotherapy and
chemotherapy (Harmey & Bouchier-Heyes 2002), the anti-VEGF
activity of bevacizumab has been shown to augment the
responsiveness of NSCLC tumors to radiotherapy and platinum-
based chemotherapy in nude mice (Kabbinavar et al. 1995). In-
vitro studies have demonstrated synergistic efficacy of
Tumoral secretion of VEGF
Endothelial cells Immune cells
Inhibition of antitumor
immune responses
Promotes proliferation,
migration, and survival
Angiogenesis
Supports tumor growth
and metastasis
Proliferation
Giant vessel formation
(lymphangiogenesis)
Promotes metastasis Promotes tumor survival
Increased permeability
Increased interstital
and intratumoral pressure
Impaired delivery
of cytotoxics
Areas of
tumour hypoxia
Hypoxia, oncogene expression, hormone production
Fig. 2 | Role of vascular endothelial growth factor (VEGF) in tumor growth. NSCLC, nonsmall cell lung cancer
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2001), and bevacizumab also appears to reverse VEGF-mediated
inhibition of dendritic cell differentiation, resulting in enhanced
antitumor immune responses (Gabrilovich et al. 1998, 1999). 
Three clinical studies investigating bevacizumab in the treatment
of NSCLC have been published to date: 
• A phase II, randomized study comparing carboplatin,
paclitaxel, and bevacizumab (7.5 mg/kg or 15 mg/kg) with
carboplatin and paclitaxel alone in 99 patients with wet IIIB
(n=15) or stage IV NSCLC (n=84) who had received no
previous chemotherapy or biotherapy (Johnson et al. 2004;
Figure 3a). The carboplatin/paclitaxel doublet was selected
for use in combination with bevacizumab for three reasons: 
– Carboplatin/paclitaxel is generally less toxic than other
platinum doublets (Schiller et al. 2002)
– When combined with antiangiogenic therapy, the
antitumor activity of carboplatin/paclitaxel is enhanced
in animal models of NSCLC and breast cancer
(Herbst et al. 1998)
– Carboplatin/paclitaxel and bevacizumab combined was 
well tolerated in a phase I study conducted in patients with
various types of advanced cancers (Margolin et al. 2001).
• A phase II/III, randomized study comparing carboplatin,
paclitaxel, and bevacizumab (15 mg/kg) with carboplatin and
paclitaxel alone in 878 previously untreated patients with wet
IIIB or stage IV NSCLC (excluding NSCLC categorized as
squamous cell carcinoma and patients who have previously
experienced hemoptysis) (Tyagi 2005; Sandler et al. 2005a,b,
2006; Dowlati et al. 2006; Figure 3b). 
• A phase I/II, single-arm study of bevacizumab and erlotinib
combined in 40 patients with wet IIIB or stage IV NSCLC
(excluding NSCLC characterized as squamous cell carcinoma)
who had relapsed after at least one platinum-based regimen
(Herbst et al. 2003, 2004, 2005; Mininberg et al. 2003; Sandler
et al. 2003, 2004b; Tsao et al. 2005; Figure 3c). Erlotinib was
selected as a combination drug with bevacizumab for the
following reasons:
– Erlotinib has shown impressive single agent activity in
recurrent stage III/IV NSCLC (Perez-Soler et al. 2004)
– Bevacizumab and erlotinib have demonstrated synergistic
activity in human colon cancer xenograft models 
(Herbst et al. 2003)
– Other HER-1/EGFR and VEGF dual blockade strategies have
demonstrated impressive antitumor activity in human tumor
xenograft models (e.g. cetuximab, an anti-HER-1/EGFR
monoclonal antibody, combined with either DC101, an anti-
VEGFR monoclonal antibody, or VEGF-antisense technology)
(Ciardiello et al. 2000; Shaheen et al. 2001; Jung et al. 2002).
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Wet IIB or
metastatic
(stage IV) NSCLC.
No previous
chemotherapy
or biotherapy (n=99).
Previously untreated
wet IIIB or metastatic
(stage IV) NSCLC
(n=830). Exclusion
of patients with
squamous tumors,
CNS metastases,
or history of
hemoptysis
Phase I
Group 1 (n=3)
Erlotinib (100 mg/day, p.o.)
Bevacizumab (7.5 mg/kg, i.v.)
Group 1 (n=3)
Erlotinib (100 mg/day, p.o.)
Bevacizumab (15 mg/kg, i.v.)
Group 1 (n=3)
Erlotinib (150 mg/day, p.o.)
Bevacizumab (15 mg/kg, i.v.)
Additional 28 patients
recruited at the
group 3 dose
Phase II
Carboplatin (AUC=6) + paclitaxel
(200 mg/m
2) q 3 w x 6 cycles
Carboplatin (AUC=6) + paclitaxel
(200 mg/m
2) q 3 w x 6 cycles
Bevacizumab
(15 mg/kg q 3 w) on PD
No crossover to
bevacizumab permitted
Carboplatin + paclitaxel (6 cycles)
+ bevacizumab (15 mg/kg)
q 3 w until PD
R
A
N
D
O
M
I
Z
E
R
A
N
D
O
M
I
Z
E
Carboplatin + paclitaxel (6 cycles)
+ bevacizumab (7.5 mg/kg)
q 3 w until PD
Carboplatin + paclitaxel (6 cycles)
+ bevacizumab (15 mg/kg)
q 3 w until PD
a | Phase II trial of carboplatin/paclitaxel ± high- or low-dose
bevacizumab in patients with wet IIIB/stage IV NSCLC
(Johnson et al. 2004)
b | Phase II/III randomized trial of carboplatin/paclitaxel plus
bevacizumab in patients with previously untreated, 
wet IIIB/stage IV, nonsquamous NSCLC (Tyagi 2005; Sandler
et al. 2005a,b)
c | Phase I/II single-arm trial of bevacizumab and erlotinib in
patients with wet IIIB/stage IV nonsquamous NSCLC who
have relapsed following platinum-based chemotherapy
(Herbst et al. 2005)
Fig. 3 | Study designs investigating bevacizumab in patients 
with NSCLC. AUC, area under the curve; CNS, central
nervous system; i.v., intravenous; NSCLC, nonsmall cell
lung cancer; PD, progressive disease; q 3 w, every 3 weeks39
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Outcomes from these three studies are reviewed in the following
sections, and efficacy endpoints are summarized in Table 5. 
In addition, there is limited evidence, only available in abstract
form at the time of writing, of preliminary results with
bevacizumab: plus gemcitabine and carboplatin (Kraut 2006);
plus gemcitabine and oxaliplatin (Davila et al. 2006); and plus
pemetrexed and carboplatin (Patel et al. 2006). 
Response rates
Bevacizumab combined with carboplatin/paclitaxel
In the phase II trial of carboplatin/paclitaxel ± bevacizumab in
previously untreated patients with wet IIIB or stage IV NSCLC,
antitumor efficacy appeared to be greatest with high-dose
bevacizumab, compared with low-dose bevacizumab (Johnson
et al. 2004; Table 6). However, the study was not sufficiently
powered to demonstrate a definitive dose–response relationship.
When responses were evaluated by the study investigators,
the overall response rate (ORR) with carboplatin/paclitaxel
plus high-dose bevacizumab was 31.5%, compared with
18.8% in patients treated with carboplatin/paclitaxel alone.
When responses were evaluated by an independent review
facility (IRF), the ORR in the high-dose bevacizumab group
was 40.0%, compared with 31.3% in patients treated with
carboplatin/paclitaxel alone.
In addition, of 19 patients in the carboplatin/paclitaxel group who
switched to bevacizumab monotherapy on disease progression,
five achieved stable disease that was maintained for >6 months. 
In the subsequent phase II/III study (Sandler et al. 2005a,b; Tyagi
2005), which excluded patients with tumors categorized as
predominantly of the squamous cell subtype (see Safety and
tolerability section below), the first interim analysis confirmed
that the addition of bevacizumab to carboplatin/paclitaxel
chemotherapy produced significantly higher response rates
compared with carboplatin/paclitaxel chemotherapy alone (ORR
27.2 vs 10.0%, P<0.0001; partial response rate: 25.8 vs 10%;
complete response rate: 1.4 vs 0%). 
Bevacizumab combined with erlotinib
In the phase I/II study of bevacizumab plus erlotinib conducted in
patients with wet IIIB and stage IV NSCLC who had relapsed
C + P (controls) (n=32) C + P + Bev (7.5 mg/kg) (n=32) C + P + Bev (15 mg/kg) (n=34)
All patients Nonsquamous All patients Nonsquamous All patients Nonsquamous
ORR (%) 18.8 20 28.1 31.8 31.5 50
Median TTP (months) 4.2 4.0 4.3 6.3 7.4 7.1
Median OS (months) 14.9 12.2 11.6 14.0 17.7 17.8
Responses shown are investigator responses.
Bev, bevacizumab; C, carboplatin; NSCLC, nonsmall cell lung cancer; ORR, overall response rate; OS, overall survival; P, paclitaxel; PFS, progression-free survival; TTP, time to progression.
Table 6 | Phase II efficacy of carboplatin and paclitaxel ± bevacizumab in patients with wet IIIB/stage IV NSCLC (Johnson et al. 2004)
Study Patient group Treatment Outcome
ORR (%) Median PFS or TTP Median OS
Phase II
(Johnson et al. 2004)
Stage IIIB/IV NSCLC of all histologic
subtypes, no previous chemotherapy
or biotherapy (n=99)
C + P 18.8 4.2 (TTP) 14.9a
C + P + Bev (7.5 mg/kg) 28.1 4.3 (TTP) 11.6b
C + P + Bev (15 mg/kg) 31.5 7.4c (TTP) 17.7
Phase II/III
(Sandler et al. 2005a,b)
Previously untreated stage IIIBIV
nonsquamous NSCLC (n=878)
C + P 10 4.5 (PFS) 10.2
C + P + Bev (15 mg/kg) 27c 6.4c (PFS) 12.5c
Phase I/II
(Herbst et al. 2005)
Recurrent stage IIIB/IV nonsquamous
NSCLC (relapsed after at least one
platinum-based regimen) (n=40)
Bev (15 mg/kg) + Erl 20 7.0 (PFS) 12.6
aPatients the C + P (control group) were allowed to cross over to treatment with bevacizumab (15 mg/kg) upon disease progression, which may explain why median survival was longer than
expected in this treatment group.
bThe majority of patients with squamous cell NSCLC were in the low-dose bevacizumab group, accounting in part for the lower survival compared with the high-dose bevacizumab group.
cDenotes significant improvement compared with C + P alone. 
Bev, bevacizumab; C, carboplatin; Erl, erlotinib; NSCLC, nonsmall cell lung cancer; ORR, overall response rate; OS, overall survival; P, paclitaxel; PFS, progression-free survival; TTP, time to
progression.
Table 5 | Efficacy of bevacizumab combinations in stage IIIB/stage IV NSCLC 
Core Evidence 2007;2(1)following platinum-based therapy (Herbst et al. 2005), the disease
control rate (all patients achieving at least stable disease) for the
entire study population (i.e. phase I and phase II combined, n=40)
was 85%. Eight patients (20%) achieved partial responses, 
26 patients (65%) achieved stable disease, and only six patients
(15%) developed progressive disease.
All eight responders had adenocarcinomas. However, 30/40
patients enrolled onto this study had adenocarcinomas (patients
with tumors classified as squamous cell carcinomas were
excluded to minimize bleeding risk), making it impossible to
ascertain whether patients with adenocarcinoma are more likely
to respond to treatment with bevacizumab plus erlotinib than
patients with other NSCLC histologic subtypes. 
Bevacizumab in other combinations
Preliminary results show partial responses in seven (31%) and
stable disease in eight (36%) of 22 evaluable patients receiving
bevacizumab in combination with gemcitabine 1000 mg/m2 plus
oxaliplatin 130 mg/m2 (Davila et al. 2006), and a partial and a
minor response in one patient each from six receiving the drug in
combination with pemetrexed 500 mg/m2 plus carboplatin (Patel
et al. 2006).
Time to progression/progression-free survival 
Bevacizumab combined with carboplatin/paclitaxel
In the phase II study (Johnson et al. 2004), the addition of high-
dose bevacizumab to carboplatin/paclitaxel chemotherapy
significantly prolonged time to progression compared with
carboplatin/paclitaxel chemotherapy alone (7.4 vs 4.2 months,
respectively; P=0.023, based on investigators’ own assessment of
disease progression). This represents a 46% reduction in the risk
of disease progression (Cox proportional hazard model). When
disease progression was assessed by the IRF the addition of high-
dose bevacizumab to carboplatin/paclitaxel chemotherapy was
shown to prolong time to progression compared with
carboplatin/paclitaxel alone, although this difference failed to
reach statistical significance (7.0 vs 5.9 months). 
The subsequent phase II/III trial (Sandler et al. 2005a,b; Tyagi
2005) confirmed that the addition of bevacizumab to
carboplatin/paclitaxel chemotherapy resulted in significantly
prolonged median progression-free survival (PFS), compared with
carboplatin/paclitaxel chemotherapy alone (6.4 vs 4.5 months,
P<0.0001).
Bevacizumab combined with erlotinib 
In the phase I/II study of bevacizumab plus erlotinib (Herbst et al.
2005), 1-year PFS was 38.0% (95% CI 24.3%, 59.6%), and
median PFS was 7.0 months. These results were very
encouraging considering that this was a cohort of extremely poor
prognosis patients with wet IIIB/stage IV NSCLC (classified as a
nonsquamous NSCLC) who had relapsed after receiving
platinum-based chemotherapy.
Overall survival 
Bevacizumab combined with carboplatin/paclitaxel
In the phase II study, addition of high-dose bevacizumab
(15 mg/kg) to first-line carboplatin/paclitaxel chemotherapy
resulted in a modest increase in overall survival compared with
chemotherapy alone (17.7 vs 14.9 months) (Johnson et al. 2004).
However, overall survival in the chemotherapy alone group was
strikingly high (14.9 months) compared with median survival
reported in cooperative phase III trials of carboplatin/paclitaxel in
similar patient cohorts (~8 months). This is possibly due to 19/32
patients in the carboplatin/paclitaxel group crossing over to
treatment with high-dose bevacizumab on disease progression
(after crossover 1-year survival in these 19 patients was 47.4%). 
The first interim analysis of data from the subsequent phase II/III
trial (Tyagi 2005) confirmed that median survival in patients
treated with carboplatin/paclitaxel plus bevacizumab followed
by bevacizumab monotherapy until disease progression
was significantly longer than in patients who received
carboplatin/paclitaxel alone (HR 0.77; 12.5 vs 10.2 months;
P=0.007). Exploratory subgroup analyses demonstrated that the
addition of bevacizumab to chemotherapy provided survival benefit
irrespective of tumor stage, weight loss, previous radiotherapy,
race, performance status, and age. However, while survival was
significantly improved in males treated with carboplatin/paclitaxel
plus bevacizumab compared with carboplatin/paclitaxel alone (HR
0.69, P=0.003), the survival advantage achieved with bevacizumab
in females failed to reach statistical significance (HR 0.96, P=0.80).
Explanations for this apparent survival difference by gender include
possible imbalances in unmeasured baseline prognostic factors
(e.g. smoking history was not collected in this study),
differences between males and females in the use of subsequent
second- and third-line therapy (only details of second-line therapy
were collected), chance alone, or may indeed may reflect a true
gender difference regarding the survival benefits offered by
bevacizumab. 
Bevacizumab combined with erlotinib
In the phase I/II study of bevacizumab plus erlotinib (Herbst et al.
2005), median overall survival was 12.6 months, and the 1-year
survival rate was 54.2% (95% CI 40.0%, 73.4%). Further studies
are now needed to confirm these encouraging data in larger
patient cohorts. 
Prognostic factors
Identifying prognostic factors will assist in the selection of
patients with NSCLC who are most likely to respond well to
treatment with bevacizumab, thus facilitating individualized
patient care. Potential prognostic factors that are currently 
under investigation in the ongoing phase II/III study of
carboplatin/paclitaxel ± bevacizumab in patients with previously
untreated wet IIIB and stage IV NSCLC (other than the squamous
cell subtype) include the following: serum VEGF, soluble E
selectin, soluble intracellular adhesion molecule-1 (ICAM), and
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basic fibroblast growth factor (bFGF) levels (Sandler et al.
2005a,b), all of which are markers for angiogenic activity. Low
baseline ICAM levels were predictive of improvements in PFS with
bevacizumab (Dowlati et al. 2006). 
In the phase I/II study of bevacizumab plus erlotinib in patients
with relapsed wet IIIB/stage IV nonsquamous NSCLC,
pretreatment serum samples were analyzed by mass
spectrometery, resulting in the identification of protein/peptide
expression patterns that discriminated between responders and
those who experienced disease progression (Salmon et al. 2005).
Additional work is planned to validate these preliminary data and
to identify which specific plasma proteins have prognostic value.
Quality of life
Of interest, there are currently no available data on quality of life
benefits in patients with NSCLC treated with bevacizumab, and in
the palliative setting, quality of life benefits are likely to be just as
important to patients as prolongation of survival. 
Safety and tolerability 
The safety and tolerability profile of bevacizumab has been
extensively investigated in NSCLC and the majority of reported
adverse events have been noted to be either manageable or not
clinically relevant. However, some safety concerns have been
raised, particularly regarding potentially life-threatening bleeding
events. Moreover, reversible posterior leukoencephalopathy
syndrome (RPLS) has been reported in clinical studies with
bevacizumab. RPLS involves leaking from brain capillaries and is
associated with hypertension, fluid retention, and the cytotoxic
effects of immunosuppressive drugs on the vascular endothelium.
Symptoms include headache, seizures, lethargy, confusion, and
visual disturbances. Although occurring in fewer than 0.1% of
patients, it is considered sufficiently serious to warrant a warning
on the prescribing information in September 2006 (Anon. 2006). 
Impact on chemotherapy-related toxicity
If bevacizumab is to be successfully incorporated into existing
chemotherapy regimens in NSCLC it is important that it does not
exacerbate chemotherapy-related toxicities. Experience to date
with bevacizumab in patients with NSCLC has shown that
combining bevacizumab with carboplatin/paclitaxel does not
increase the incidence or severity of nausea, vomiting, renal
toxicity, or neuropathy, which are typically associated with
chemotherapy. However, the addition of bevacizumab 
to carboplatin/paclitaxel chemotherapy is associated with 
an apparent dose-dependent increased risk of
leukopenia/neutropenia, and a slight increase in the incidence of
diarrhea and minor systemic events, including fever, headache,
rash, and chills (Johnson et al. 2004). 
Bleeding events
In the phase II study of carboplatin/paclitaxel ± bevacizumab
(Johnson et al. 2004), two distinct patterns of bleeding were
observed: minor mucocutaneous hemorrhage, and severe
and sometimes fatal bleeding (hemoptysis or hematemesis).
The most common mucocutaneous bleeding was National
Cancer Institute Common Toxicity Criteria (NCI-CTC) grade
1–2 epistaxis, which was reported in 31% of patients treated
with low-dose bevacizumab, and 44% of patients treated
with high-dose bevacizumab, compared with only 6% of
patients treated with chemotherapy alone. None of these
minor bleeding events required a change in bevacizumab
administration. Of greater concern, six patients treated with
bevacizumab experienced life-threatening bleeding, which
was fatal in four patients. These life-threatening bleeding
events were more frequent in the low-dose bevacizumab
group (5/6 cases) than the high-dose bevacizumab group (1/6
cases), occurred both early (≤60 days) and late (≥180 days) in
treatment, and were more frequent in patients with NSCLC
classified as squamous cell carcinomas (4/13 patients)
than patients with adenocarcimonas (2/54 patients).
Consequently, patients with squamous cell NSCLC were
excluded in subsequent studies of bevacizumab in NSCLC
(Johnson et al. 2004). 
In the subsequent phase II/III trial of carboplatin/paclitaxel ±
bevacizumab which excluded patients with squamous cell
histology (Sandler et al. 2005a,b), the incidence of severe (≥grade
3) hemoptysis was 1.9% (8/420) in the carboplatin/paclitaxel plus
bevacizumab group versus 0.2% (1/427) in the chemotherapy
alone group (P<0.04). Of 420 patients who were treated with
bevacizumab, seven died as a result of bleeding events (five
cases of hemoptysis, two cases of GI bleeding), compared with
1/427 patients who were treated with chemotherapy alone.
However, this study indicates that the exclusion of patients with
predominantly squamous cell disease drastically reduces the risk
of severe and fatal pulmonary hemorrhage. A retrospective
analysis of the patients in this study revealed ten cases of
pulmonary hemorrhage in 425 patients who received
bevacizumab, six of which occurred within 150 days of beginning
treatment, and no evidence of clinical risk factors at baseline
(Sandler et al. 2006). 
In the phase I/II trial of bevacizumab and erlotinib combined,
which also excluded patients with squamous cell histology
(Herbst et al. 2005), only 6% of patients receiving bevacizumab
15 mg/kg developed mild epistaxis, and importantly there were no
life-threatening bleeding events. 
Proteinuria
Treatment with bevacizumab in patients with NSCLC is
associated with an increased incidence of proteinuria. In the
phase II trial of carboplatin/paclitaxel ± bevacizumab (Johnson et
al. 2004) 7/32 patients in the low-dose bevacizumab group and
14/32 patients in the high-dose bevacizumab group developed
asymptomatic proteinuria, compared with 2/32 patients in the
chemotherapy alone group. Similarly, in the phase I/II trial of
bevacizumab combined with erlotinib (Herbst et al. 2005), 9% of
patients who received the phase II dose of bevacizumab
(15 mg/kg) developed proteinuria. 
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As reported in trials in other solid tumor indications, treatment
with bevacizumab in patients with NSCLC appears to be
associated with an increased risk of hypertension. In the phase II
study of carboplatin/paclitaxel ± bevacizumab (Johnson et al.
2005), 5/32 patients treated with high-dose bevacizumab and
6/34 patients treated with low-dose bevacizumab developed
hypertension, compared with only 1/32 patients treated with
chemotherapy alone. Of those patients who developed
hypertension, the greatest increases in systolic blood pressure
were observed in patients who received high-dose bevacizumab.
However, no patient on this phase II study discontinued treatment
due to hypertension.
In the subsequent phase II/III study (Sandler et al. 2005a,b;
Tyagi 2005), the incidence of grade 3 hypertension was
significantly higher in patients treated with carboplatin/paclitaxel
plus bevacizumab, compared with those who were treated with
chemotherapy alone (6 vs 0.7%, P≤0.001), and in the phase I/II
study of bevacizumab plus erlotinib (Herbst et al. 2005), a
similar proportion of patients (2/40) developed grade 3–4
hypertension.
Although treatment with bevacizumab is associated with
hypertension, it can be effectively managed with oral
antihypertension medications such as angiotensin-converting
enzyme (ACE) inhibitors or calcium channel blockers. In addition,
data from a study investigating long-term treatment with
bevacizumab in patients with a range of different solid tumors
suggest that bevacizumab-related hypertension decreases with
long-term use (Langmuir et al. 2002). 
Thrombotic events 
In the phase II study of carboplatin/paclitaxel ± bevacizumab
(Johnson et al. 2004) there was a slight increase in the frequency
of thrombotic events in patients who were treated with low- and
high-dose bevacizumab, compared with those who received
chemotherapy alone (9.4% in the chemotherapy alone group,
12.5% in the low-dose bevacizumab group, 17.6% in the high-
dose bevacizumab group). However, in the subsequent phase II/III
study conducted in patients with nonsquamous NSCLC (Sandler
et al. 2005a,b), no significant increase in the frequency of grade
≥3 arterial thrombosis or grade ≥3 venous thrombosis was
observed in patients treated with carboplatin/paclitaxel plus
bevacizumab, compared with those who received chemotherapy
alone (arterial thrombosis 1.9 vs 1.0%; venous thrombosis 3.8 vs
3.0%). Moreover, no thrombotic events were recorded in the
phase I/II study of bevacizumab plus erlotinib in 40 patients with
relapsed nonsquamous NSCLC (Herbst et al. 2005). However,
in a pooled analysis of data from five randomized trials involving
patients with metastatic breast cancer, colorectal cancer, 
and NSCLC, bevacizumab and chemotherapy combined was
associated with a significantly higher incidence of arterial
thrombotic events compared with chemotherapy alone (3.8 vs
1.7%, P<0.01), especially in patients ≥65 years old with a prior
history of thromboembolic events (Skillings et al. 2005). 
Ongoing clinical development
The results of the first interim analysis of the phase II/III
trial demonstrating significantly prolonged survival in patients
treated with carboplatin/paclitaxel plus bevacizumab compared
with chemotherapy alone has prompted the initiation of a range of
phase II and phase III studies investigating the potential for
bevacizumab in combination with other platinum-based doublets
in the first-line treatment of wet IIIB/stage IV NSCLC (Treat 2005).
The doublets under investigation include: carboplatin/gemcitabine,
cisplatin/gemcitabine, oxaliplatin/gemcitabine, and carboplatin/
pemetrexed (Table 7). The potential for bevacizumab in
combination with single-agent chemotherapy (docetaxel or
pemetrexed) in the second-line treatment of advanced stage IIIB/IV
NSCLC is also being explored (Table 7). 
Based on the encouraging data from the phase I/II single-arm
study of bevacizumab plus erlotinib (Herbst et al. 2005), three
more studies are underway to further evaluate the clinical
potential of this combination in the second-line treatment of 
stage IIIB/IV NSCLC: 
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Table 7 | Planned and ongoing studies with bevacizumab for
the treatment of stage IIIB/IV NSCLC
Study design Inclusion criteria
Phase II
Single-arm study of carboplatin,
gemcitabine, and bevacizumab in
advanced NSCLC 
Stage IIIB/IV NSCLC, newly
diagnosed or recurrent after
previous surgery and/or radiotherapy 
Single-arm study of oxaliplatin,
gemcitabine, and bevacizumab in the
first-line treatment of advanced
NSCLC 
Previously untreated stage IIIB/IV
NSCLC, excluding patients with
squamous cell histology 
Randomized study comparing
bevacizumab + chemotherapy
(docetaxel or pemetrexed) vs
bevacizumab + erlotinib vs
chemotherapy alone in patients with
previously treated advanced NSCLC 
Stage IIIB/IV, recurrent NSCLC 
with progression after previous
platinum-based chemotherapy or
adjuvant chemotherapy 
Single-arm study of carboplatin,
pemetrexed, and bevacizumab in
patients with NSCLC 
Stage IIIB, stage IV, or recurrent
NSCLC, no prior systemic
chemotherapy, exclusion of patients
with squamous cell histology 
Phase III
Randomized study of cisplatin 
and gemcitabine ± bevacizumab 
(7.5 mg/kg or 15 mg/kg) in advanced
NSCLC (AVAiL)
Stage IIIB/IV NSCLC, newly
diagnosed or recurrent after
previous surgery and/or
radiotherapy 
Randomized, placebo-controlled study
of bevacizumab + erlotinib vs erlotinib
alone in the second-line treatment of
advanced NSCLC 
Radiographic progression during 
or after first-line chemotherapy for
stage IIIB/IV NSCLC 
Randomized, placebo-controlled study
of platinum-based chemotherapy
combined with bevacizumab followed
by bevacizumab + erlotinib vs
bevacizumab + erlotinib placebo in the
first-line treatment of advanced NSCLC
Stage IIIB, stage IV, or recurrent
NSCLC, no prior systemic
chemotherapy, exclusion of
patients with squamous cell
histology43
• A phase III, randomized, double-blind, placebo-controlled
study investigating the safety and efficacy of bevacizumab
combined with platinum-based chemotherapy doublets
followed by treatment with either bevacizumab plus erlotinib
or bevacizumab plus placebo to disease progression in the
first-line treatment of patients with stage IIIB/IV NSCLC 
(other than the squamous cell subtype)
• A phase III randomized, double-blind, placebo-controlled
study comparing the safety and efficacy of bevacizumab plus
erlotinib compared with erlotinib plus placebo in the second-
line treatment of patients with stage IIIB/IV nonsquamous
NSCLC following failure of first-line chemotherapy. This study
will also investigate any potential pharmacokinetic interactions
between these agents 
• A phase II randomized trial comparing the safety and efficacy
of bevacizumab plus erlotinib versus bevacizumab plus
chemotherapy (docetaxel or pemetrexed) versus
chemotherapy alone (docetaxel or pemetrexed) in the
treatment of relapsed or refractory nonsquamous NSCLC
Economic evidence 
The economic burden of NSCLC is huge. Not only are the direct
costs of surgical resections, radiotherapy, and drug therapy high,
the secondary costs associated with hospitalization, postoperative
care, and management of adverse effects of chemotherapy are
considerable. In addition, there are the societal costs associated
with the impaired ability to work. Pharmacoeconomic data are
readily available comparing the cost effectiveness of various
different chemotherapy regimens in different patient subgroups
(e.g. Clegg et al. 2001; Saglam et al. 2002; Szczepura 2002;
Holmes et al. 2004; Neymark et al. 2005). Some preliminary
pharmacoeconomic data regarding the use of bevacizumab in the
treatment of NSCLC are available in abstract form.
Using the results of Sandler et al. (2005a,b), the incremental cost
effectiveness of adding bevacizumab to carboplatin plus
paclitaxel was calculated, based on Medicare reimbursement
cost for January 2005 (Grusenmeyer & Gralla 2006). With a
median overall survival increase of 2.3 months, the cost per life-
year gained with bevacizumab was $US345 762. Reimbursement
of bevacizumab would need to be $US14.70/10 mg to reach a
threshold of $US100 000 per year of life gained, 74% lower than
the 2005 Medicare value of $US57.08/10 mg.
Another study from the direct payer perspective using 2005
Canadian wholesale prices demonstrated a cost of $Can47 250
per patient with metastatic lung cancer for bevacizumab relative
to conventional therapy (Drucker et al. 2006). The total lifetime
cost to the Canadian healthcare system was estimated to be
$Can262 million if bevacizumab was used for lung, breast, and
colorectal cancer.
These preliminary results clearly reflect the drug acquisition cost
for bevacizumab, reflecting the high cost of monoclonal antibody
production.
Patient group/population
Patients with advanced, inoperable, stage IIIB/IV NSCLC
Previously untreated patients
For patients with wet IIIB/stage IV NSCLC, first-line treatment with
a platinum-based chemotherapy agent (carboplatin or cisplatin)
plus a new cytotoxic agent (e.g. docetaxel, paclitaxel, gemcitabine,
or vinorelbine) has been the accepted standard of care in 
most countries. The phase II/III, randomized trial investigating the
use of carboplatin/paclitaxel ± bevacizumab in patients with
nonsquamous NSCLC is the first study to demonstrate a
statistically significant survival advantage with a targeted agent 
plus chemotherapy versus chemotherapy alone. Consequently,
bevacizumab combined with carboplatin/ paclitaxel is now the new
Eastern Cooperative Oncology Group (ECOG) reference standard
for the treatment of patients with previously untreated wet
IIIB/stage IV nonsquamous NSCLC (Tyagi 2005). However, the
safety of bevacizumab in combination with other chemotherapy
combinations remains to be explored. 
Patients with relapsed disease
For patients with wet IIIB/stage IV, nonsquamous NSCLC who have
relapsed following first-line treatment with platinum-based
chemotherapy, preliminary phase I/II data indicate that the
combination of bevacizumab with the HER-1/EGFR inhibitor erlotinib
was well tolerated, resulting in encouraging responses (Herbst et al.
2005). Previous studies have suggested that HER-1/EGFR inhibitors
provide the greatest efficacy in females and patients who have never
smoked. However, in this study the response rates were similar in
males and females (26.3 and 14.3%, respectively), and in
current/previous smokers versus life-long nonsmokers (19.4 vs
22.2%), suggesting that bevacizumab in combination with
erlotinib is effective in a wider patient population than erlotinib
alone. However, these preliminary data should be interpreted with
caution due to the low number of patients (n=40) involved. 
Patient selection to minimize pulmonary bleeding risk
The phase II study of carboplatin/paclitaxel ± bevacizumab
(Johnson et al. 2004) demonstrated that patients with NSCLC
classified as the squamous cell subtype (tumors of mixed
histologies were classified by the predominant cell type) may not
be suitable candidates for treatment with bevacizumab because
they are at increased risk of experiencing serious, potentially life-
threatening bleeding. In clinical practice, rigorous patient
selection procedures will be extremely important in minimizing
bleeding risk. Patients with NSCLC who should not receive
bevacizumab because they are at increased risk of experiencing
serious bleeding events include those with squamous cell
carcinomas, brain metastases, a prior history of gross hemoptysis
events, and patients receiving anticoagulants. 
Patients with earlier-stage NSCLC 
The encouraging efficacy of bevacizumab combined with either
platinum-based chemotherapy or erlotinib demonstrated in
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use of bevacizumab in patients with earlier-stage, operable
NSCLC (Belani & Ramalingam 2005; Kerr 2005; Kris 2005; Martins
2005; Tyagi 2005). This includes using bevacizumab in both the
neoadjuvant setting (i.e. in combination with chemotherapy or
radiotherapy to reduce the tumor before surgery), and the adjuvant
setting (after surgery) to treat residual disease.
There is a strong rationale for using bevacizumab in the adjuvant
setting. Following surgical resection of the primary tumor,
metastases can be present yet undetectable, ultimately leading to
relapse. As these metastases are dependent on VEGF for the
angiogenic switch to malignant growth, adjuvant treatment with
bevacizumab could, in concept, reduce the risk of relapse. In
addition, adjuvant chemotherapy is associated with significant
toxicity, which can be unacceptable to patients who have
undergone surgery and are potentially disease-free. For these
patients, postoperative bevacizumab maintenance therapy is
likely to be a better tolerated and therefore perhaps more
attractive therapeutic option. 
As already discussed, patients with NSCLC tumors classified as
having predominant squamous cell histology should not be
treated with bevacizumab-containing regimens because of the
unacceptably high risk of serious pulmonary hemorrhage.
However, in the postoperative (adjuvant) setting, the use of
bevacizumab could potentially be extended to patients with both
squamous and nonsquamous NSCLC for treating minimal
residual disease (MRD) following neoadjuvant chemotherapy and
surgical resection (Kris 2005). This is because hemoptysis is
thought to be a consequence of bevacizumab-induced tumor
disintegration and therefore once the tumor has been almost
completely eliminated, even patients with squamous NSCLC
could potentially benefit from the antitumor efficacy of
bevacizumab without the associated bleeding risks (Kris 2005). 
A small phase II trial [Bevacizumab and Chemotherapy for
Operable NSCLC (BEACON)] has recently opened at Memorial
Sloan-Kettering Cancer Center (MSKCC), exploring the use of
cisplatin, docetaxel plus bevacizumab versus cisplatin and
docetaxel alone as neoadjuvant therapy prior to surgical resection
and bevacizumab maintenance therapy in patients with stage
IA–IIIA operable NSCLC (Kris 2005). In addition, a large ECOG
intergroup trial of chemotherapy plus bevacizumab versus
chemotherapy alone as adjuvant therapy following complete
surgical resection in patients with stage IB–IIIA NSCLC began in
spring 2006. 
Dosage, administration, and formulation
Bevacizumab (Avastin) should be given as an intravenous infusion
of 15 mg/kg every 3 weeks in combination with carboplatin and
paclitaxel (Anon. 2006). The drug should be discontinued in
patients who experience gastrointestinal perforation, serious
bleeding, delayed wound healing, thromboembolic event,
nephrotic syndrome, hypertensive crisis, or RPLS, in whom
antihypertensive treatment should also be initiated if hypertension
is present.
Place in therapy
For more than a decade, platinum-based chemotherapy doublets
have been the standard of care for patients with wet IIIB/stage IV
NSCLC, offering only modest improvements in survival compared
with best supportive care. Now, based on the first interim analysis
of data from a phase II/III trial (Tyagi 2005), bevacizumab is set to
dramatically influence the treatment of wet IIIB/stage IV NSCLC. In
this study, the addition of bevacizumab to carboplatin/paclitaxel
chemotherapy significantly improved the response rate,
progression-free survival, and overall survival compared with
chemotherapy alone (2-month survival advantage). Consequently,
the combination of bevacizumab, carboplatin, and paclitaxel is
already the ECOG reference standard for the first-line treatment of
wet IIIB/stage IV nonsquamous NSCLC exclusive of squamous
cell histology. Treatment guidelines will therefore require updating
to take into account the benefits of bevacizumab in fulfilling the
previously unmet need for an agent to improve survival in this
group of patients with poor prognosis. Indeed, in October 2005,
the National Comprehensive Cancer Network (NCCN) released
newly updated clinical practice guidelines (NCCN 2006) to include
bevacizumab combined with chemotherapy as first-line treatment
for advanced NSCLC, based on the results of the phase II/III trial
(Sandler et al. 2005a,b) investigating bevacizumab ± carboplatin
plus paclitaxel in patients with previously untreated wet IIIB and
stage IV NSCLC. Bevacizumab was approved in October 2006 for
first-line use in combination with carboplatin and paclitaxel in
patients with unresectable, locally advanced, recurrent, or
metastatic NSCLC. 
The synergistic antitumor efficacy of bevacizumab in combination
with chemotherapy is thought to be due not only to the
antiangiogenic effects of the drug, but also the reduction in
vascular permeability, which in turn reduces tumor interstitial
pressure, enabling chemotherapy drugs to penetrate the tumor
more efficiently (Jain 2005). 
Preliminary phase I/II data also suggest that bevacizumab
combined with the HER-1/EGFR inhibitor erlotinib is well tolerated
and could potentially improve outcomes in patients with
nonsquamous NSCLC who have relapsed following first-line
platinum-based chemotherapy. The results of the ongoing,
randomized, phase III trial of bevacizumab plus erlotinib versus
erlotinib monotherapy in the second-line treatment of wet IIIB/ stage
IV nonsquamous NSCLC will be instrumental in determining the
potential for bevacizumab plus erlotinib in this indication (Table 7). 
The encouraging results obtained with bevacizumab in the
treatment of advanced, inoperable NSCLC has challenged
investigators to start exploring the wider use of this drug in patients
with earlier-stage, operable disease. As angiogenesis is an
essential component of wound healing, the timing of bevacizumab
therapy relative to surgery is likely to be critical in minimizing
postoperative wound healing complications. Experience with
bevacizumab in the adjuvant treatment of patients with colorectal
cancer (Scappaticci et al. 2004) indicates that treatment with
bevacizumab should not be initiated for at least 28 days following
major surgery, and not until the surgical wound has healed. 
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Bleeding events (in particular serious pulmonary hemorrhage) are
the main safety concern associated with bevacizumab in the
treatment of NSCLC. The currently available evidence indicates
that patients with NSCLC classified as having squamous cell
histology should not receive bevacizumab as they are at
increased risk of potentially life-threatening bleeding episodes. It
is important to note that the phase II/III pivotal trial investigating
bevacizumab combined with carboplatin/paclitaxel
chemotherapy assessed tumors of mixed histology by their
predominant cell type. However, as discussed, bevacizumab
could in concept be useful in patients with squamous NSCLC
tumors for the postsurgical treatment of MRD, as bevacizumab-
induced bleeding is thought to be due to tumor disintegration,
rather than clotting disturbances. 
Bevacizumab may also have potential in combination with
radiotherapy in NSCLC. The antitumor efficacy of ionizing radiation
is dependent on the tumor tissue being sufficiently oxygenated.
The chaotic nature by which the tumor vasculature is laid down
results in suboptimal delivery of oxygen to the tumor and areas of
relative hypoxia that are resistant to the therapeutic effects of
ionizing radiation. Inhibition of VEGF with bevacizumab normalizes
the tumor vasculature (Poon et al. 2001), ensuring more effective
tumor oxygenation, which in turn is likely to enhance the
antitumoral effects of radiotherapy. Of interest, a series of studies
conducted in animal models of human tumors demonstrated that
bevacizumab and radiotherapy combined resulted in a greater
delay in tumor growth, compared with either bevacizumab alone 
or radiotherapy alone (Hoang et al. 2005a,b). These encouraging 
data warrant clinical studies to investigate the potential for
bevacizumab to augment the efficacy of radiotherapy for NSCLC
in clinical practice. 
Antiangiogenic agents are hypothetically less susceptible to multi
drug resistance mechanisms than cytotoxic agents because they
target the tumor vasculature, rather than the tumor itself.
However, tumors are fully capable of circumventing the
antiangiogenic effect of a single agent by utilizing alternative
angiogenic pathways. It therefore seems likely that combinations
of antiangiogenic agents targeting different angiogenic pathways
will prove to be clinically advantageous in the future (Kris 2005). 
In addition, it has been hypothesized that the combination of a
VEGF inhibitor such as bevacizumab and a VEGFR tyrosine
kinase inhibitor will produce supraadditive antitumor efficacy in
patients. This hypothesis is supported by the results of a phase I
study of sorafenib (a VEGFR tyrosine kinase inhibitor) combined
with bevacizumab in patients with advanced solid tumors
(Posadas et al. 2005a,b).
Overall, the current evidence base suggests that bevacizumab
could have a significant impact on the treatment of NSCLC.
Rigorous patient selection will be required to minimize bleeding
risks, and analysis of prognostic factors is likely to facilitate the
identification of patients who are most likely to benefit from
bevacizumab therapy, thus enabling a more individualized
approach to patient care. This approach may be particularly
necessary to ensure the most cost-effective use of the drug.
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